company background image
JANX logo

Janux Therapeutics NasdaqGM:JANX Stock Report

Last Price

US$50.31

Market Cap

US$2.6b

7D

3.2%

1Y

445.1%

Updated

24 Nov, 2024

Data

Company Financials +

Janux Therapeutics, Inc.

NasdaqGM:JANX Stock Report

Market Cap: US$2.6b

JANX Stock Overview

A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. More details

JANX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Janux Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Janux Therapeutics
Historical stock prices
Current Share PriceUS$50.31
52 Week HighUS$65.60
52 Week LowUS$7.79
Beta3.52
11 Month Change-5.80%
3 Month Change8.45%
1 Year Change445.07%
33 Year Change184.88%
5 Year Changen/a
Change since IPO100.04%

Recent News & Updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Recent updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Shareholder Returns

JANXUS BiotechsUS Market
7D3.2%2.5%2.2%
1Y445.1%16.1%31.6%

Return vs Industry: JANX exceeded the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: JANX exceeded the US Market which returned 31.7% over the past year.

Price Volatility

Is JANX's price volatile compared to industry and market?
JANX volatility
JANX Average Weekly Movement7.3%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: JANX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: JANX's weekly volatility has decreased from 34% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201776David Campbellwww.januxrx.com

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products.

Janux Therapeutics, Inc. Fundamentals Summary

How do Janux Therapeutics's earnings and revenue compare to its market cap?
JANX fundamental statistics
Market capUS$2.64b
Earnings (TTM)-US$60.54m
Revenue (TTM)US$13.05m

202.3x

P/S Ratio

-43.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JANX income statement (TTM)
RevenueUS$13.05m
Cost of RevenueUS$59.82m
Gross Profit-US$46.77m
Other ExpensesUS$13.76m
Earnings-US$60.54m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.15
Gross Margin-358.45%
Net Profit Margin-463.91%
Debt/Equity Ratio0%

How did JANX perform over the long term?

See historical performance and comparison